Aytu Biopharma Agrees to Rosemont Buyout
Aytu BioPharma reported fiscal first-quarter results alongside an all-cash acquisition agreement with Rosemont Pharmaceuticals.
Updated on Nov. 17, 2026 in Healthcare

Aytu BioPharma reported first-quarter revenue of $14.84 million, up 6.9% year over year, with a loss of $0.20 per share. The company also agreed to be acquired by Rosemont Pharmaceuticals for $2.70 per share in an all-cash transaction valued at approximately $56 million.
Why it matters
The deal would transfer control of Aytu's ADHD and pediatric product lines to Rosemont if completed. Aytu's board unanimously approved the transaction, and the company said the pending merger is the reason it will not hold an earnings call.
Aytu reported a net loss of $3.9 million and EXXUA net revenue of $4.9 million, up 24.5% sequentially, while the ADHD portfolio fell to $7.7 million from $13.2 million a year earlier. Whether shareholders tender enough shares to reach the majority threshold has not yet been determined.
The players
Aytu BioPharma
Aytu BioPharma is a specialty pharmaceutical company whose products include the EXXUA ADHD treatment and a pediatric portfolio.
Rosemont Pharmaceuticals
Rosemont Pharmaceuticals is the pharmaceutical company that agreed to acquire Aytu BioPharma in an all-cash transaction.
The details
Rosemont Pharmaceuticals will offer $2.70 per Aytu share in the all-cash deal. Aytu will not hold an earnings conference call on its quarterly results because the merger is pending.
Timeline
Monday, November 16, 2026: Aytu reports Q1 fiscal 2027 results and announces the acquisition.
End of 2026: Expected closing of the Rosemont acquisition, subject to customary conditions.
Market Landscape
The transaction reflects a pattern in which larger drugmakers acquire smaller publicly traded specialty pharmaceutical companies for their established product lines. It positions Rosemont to take on Aytu's ADHD and pediatric portfolio in a market where branded therapies compete on prescription growth.
For shareholders, the $2.70 per share offer determines what they receive if they tender their shares. Patients and prescribers using EXXUA and Aytu's pediatric products will see the brand move under Rosemont's ownership if the deal closes.
The takeaway
Investors weighing Aytu should focus on the $2.70 per share offer, since the buyout price is the main factor in their decision to tender shares. The company's ADHD revenue decline and growing EXXUA prescriptions are the two trends to watch as the deal proceeds.
What happens next
Closing of the Rosemont acquisition is expected by the end of 2026, subject to the tender of a majority of Aytu's outstanding shares.
Further reading
For more on the sector, see Healthcare coverage of pharmaceutical deals.






